Pluristem Therapeutics, Inc. (PSTI)
Stock Price:
$10.47 USD
-0.24 (-2.24%)
Updated Oct 21, 2020 10:30 AM EDT - Market open
Key Info
| Market Cap |
267.56M |
| Revenue (ttm) |
23,000 |
| Net Income (ttm) |
-29.15M |
| Shares Out |
25.55M |
| EPS (ttm) |
-1.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$10.47 |
| Previous Close |
$10.71 |
| Change ($) |
-0.24 |
| Change (%) |
-2.24% |
| Day's Open |
10.75 |
| Day's Range |
10.47 - 10.87 |
| Day's Volume |
58,923 |
| 52-Week Range |
2.82 - 13.29 |
More Stats
| Market Cap |
267.56M |
| Enterprise Value |
222.80M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.55M |
| Float |
20.31M |
| EPS (basic) |
-1.60 |
| EPS (diluted) |
-1.60 |
| FCF / Share |
-1.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.14M |
| Short Ratio |
3.88 |
| Short % of Float |
5.64% |
| Beta |
2.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
11,632.94 |
| PB Ratio |
5.07 |
| Revenue |
23,000 |
| Operating Income |
-29.48M |
| Net Income |
-29.15M |
| Free Cash Flow |
-26.64M |
| Net Cash |
44.75M |
| Net Cash / Share |
1.75 |
| Gross Margin |
100.00% |
| Operating Margin |
-128,156.52% |
| Profit Margin |
-126,747.80% |
| FCF Margin |
-115,821.74% |
| ROA |
-38.05% |
| ROE |
-74.82% |
| ROIC |
-130.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.00*
(33.72% upside)
Low
12.0
Current: $10.47
High
16.0
Target: 14.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.02 | 0.05 | 0.05 | - | 2.85 | 0.38 | 0.38 | 0.68 | 0.72 | - |
| Revenue Growth | -57.41% | 8% | - | - | 651.19% | 0% | -44.18% | -5.17% | - | - |
| Gross Profit | 0.02 | 0.05 | 0.05 | - | 2.75 | 0.37 | 0.37 | 0.66 | 0.70 | - |
| Operating Income | -29.48 | -35.53 | -33.73 | -28.02 | -23.32 | -25.27 | -27.85 | -22.22 | -15.03 | -11.11 |
| Net Income | -29.15 | -35.31 | -26.13 | -27.81 | -23.25 | -24.68 | -26.93 | -21.16 | -14.79 | -10.85 |
| Shares Outstanding | 18.20 | 12.33 | 10.59 | 8.74 | 7.95 | 7.03 | 6.35 | 5.55 | 4.40 | 3.12 |
| Earnings Per Share | -1.60 | -2.90 | -2.50 | -3.20 | -2.90 | -3.50 | -4.20 | -3.80 | -3.40 | -3.50 |
| Operating Cash Flow | -26.37 | -29.45 | -21.38 | -21.61 | -18.52 | -20.61 | -19.12 | -16.89 | -3.28 | -5.76 |
| Capital Expenditures | -0.27 | -0.24 | -0.34 | -0.35 | -1.72 | -0.81 | -1.57 | -4.31 | -1.48 | -0.93 |
| Free Cash Flow | -26.64 | -29.69 | -21.72 | -21.96 | -20.24 | -21.42 | -20.69 | -21.20 | -4.76 | -6.69 |
| Cash & Equivalents | 46.34 | 24.40 | 30.59 | 26.67 | 32.75 | 53.12 | 58.82 | 54.21 | 37.81 | 42.83 |
| Total Debt | 1.59 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 44.75 | 24.40 | 30.59 | 26.67 | 32.75 | 53.12 | 58.82 | 54.21 | 37.81 | 42.83 |
| Assets | 65.53 | 31.31 | 38.96 | 37.53 | 45.94 | 68.16 | 74.02 | 68.32 | 47.42 | 46.02 |
| Liabilities | 9.43 | 9.49 | 10.45 | 7.28 | 7.79 | 10.01 | 11.90 | 10.85 | 9.68 | 2.59 |
| Book Value | 56.10 | 21.82 | 28.51 | 30.25 | 38.16 | 58.14 | 62.12 | 57.47 | 37.74 | 43.42 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pluristem Therapeutics, Inc. |
| Country |
Israel |
| Employees |
146 |
| CEO |
Yaky Yanay |
Stock Information
| Ticker Symbol |
PSTI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PSTI |
Description
Pluristem Therapeutics, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.